In:
Frontiers in Oncology, Frontiers Media SA, Vol. 11 ( 2021-8-16)
Abstract:
Co-mutations was associated with poor response to EGFR-TKIs. First-generation EGFR-TKIs combined with chemotherapy was reported to be more effective than TKIs alone in advanced lung adenocarcinoma patients. Objective This retrospective study aimed to explore whether EGFR -mutant patients with co-mutations can benefit from EGFR-TKIs plus chemotherapy. Patients and Methods We retrospectively collected data of 137 EGFR -mutant patients with advanced lung adenocarcinoma who underwent next-generation sequencing in our hospital in 2018. Among them, 96 were treated with EGFR–TKIs alone and 41 received EGFR–TKIs plus chemotherapy. We analyzed the progression-free survival (PFS) of patients with co-mutations using different treatments. Results Concurrent TP53 mutations, especially exon 4 and 6, were associated with a markedly shorter time to progression on EGFR-TKI monotherapy (11.4 months vs . 16.6 months, P =0.003), while EGFR–TKIs plus chemotherapy would benefit those patients more (with TP53: 11.4 months vs . 19.1 months, P =0.001, HR=0.407; without TP53 : 16.6 months vs . 18.9 months, P =0.379, HR=0.706). The incidence of T790M after resistance was equal in patients treated with different treatments (53% vs . 53%, P =0.985). Conclusions In our study, concurrent TP53 mutations were found to be risk factors for EGFR-TKI monotherapy, but TKI combined with chemotherapy could eliminate this heterogeneity.
Type of Medium:
Online Resource
ISSN:
2234-943X
DOI:
10.3389/fonc.2021.681429
DOI:
10.3389/fonc.2021.681429.s001
Language:
Unknown
Publisher:
Frontiers Media SA
Publication Date:
2021
detail.hit.zdb_id:
2649216-7
